<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS135056</article-id>
<article-id pub-id-type="doi">10.1101/2021.09.14.460211</article-id>
<article-id pub-id-type="archive">PPR394258</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Prateek</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhardwaj</surname>
<given-names>Taniya</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giri</surname>
<given-names>Rajanish</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1">
<label>1</label>Indian Institute of Technology Mandi, School of Basic Sciences, VPO Kamand, Himachal Pradesh 175005, India</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<label>*</label>
<bold>Correspondence:</bold> Dr. Rajanish Giri, School of Basic Sciences, Indian Institute of Technology Mandi, Himachal Pradesh 175005, India. <email>rajanishgiri@iitmandi.ac.in</email>. Telephone number: 01905-267134, Fax number: 01905-267138</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>14</day>
<month>09</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">One of the major virulence factors of SARS-CoV-2, NSP1, is a vital drug target due to its role in host immune evasion through multiple pathways. NSP1 protein is associated with inhibiting host mRNA translation by binding to the small subunit of ribosome through its C-terminal region. Previously, we have shown the structural dynamics of NSP1 C-terminal region (NSP1-CTR) in different physiological environments. So, it would be very interesting to investigate the druggable compounds that could bind with NSP1-CTR. Here, in this article, we have performed the different spectroscopic technique-based binding assays of an anticancer drug Mitoxantrone dihydrochloride (MTX) against the NSP1-CTR. We have also performed molecular docking followed by computational simulations with two different forcefields up to one microsecond. Overall, our results have suggested good binding between NSP1-CTR and MTX and may have implications in developing therapeutic strategies targeting NSP1 protein of SARS-CoV-2.</p>
</abstract>
<kwd-group>
<kwd>CD spectroscopy</kwd>
<kwd>Fluorescence spectroscopy</kwd>
<kwd>Fluorescence anisotropy</kwd>
<kwd>Molecular Dynamics Simulations</kwd>
<kwd>Drug design</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Non-structural proteins (NSPs) of coronaviruses exclusively carry out replication and translation of viral genome, hence they are considered to be one of the prime targets for drug discovery <sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup>. SARS-CoV-2 NSP1 is the first protein to be translated as a part of polyprotein 1a and 1ab, and is considered important as it works to suppress the host immune system <sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup>. It restricts the host mRNA binding to ribosome by associating with the 40S subunit of host cell using its C-terminal region (CTR) <sup>
<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>
</sup>. Upon interaction with ribosome, the NSP1-CTR partially gains α-helical structure propensity <sup>
<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>
</sup>. In our previous study, we observed that NSP1-CTR remains in disordered conformation in isolation and is found to adopt a secondary structure in different environments <sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>. It also interacts with mRNA nuclear exporter heterodimer NXF1-NXT1 and hampers the association of mRNA with NXF1, resulting in the abolishment of NXF1 docking on nuclear pore complex <sup>
<xref ref-type="bibr" rid="R6">6</xref>
</sup>. Recently, a study exposed the detailed insights of host translation inhibition where the eukaryotic translation initiation factors (eIF3 and eIF4F) allosterically control the NSP1 association with ribosome in the early stages of translation in absence of mRNA <sup>
<xref ref-type="bibr" rid="R7">7</xref>
</sup>. Moreover, mutagenesis-based studies have revealed several key residues in its CTR that are responsible for its interaction with ribosome and abrogation of the translational activity <sup>
<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R6">6</xref>
</sup>. All these facts make NSP1-CTR an essential drug target that can lead to ultimate blockage of NSP1 activity.</p>
<p id="P3">Many studies for drug discovery have been performed in the last few months of pandemic, including the drug repurposing as a time and cost-effective approach <sup>
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>
</sup>. Drug repurposing is the most effective approach to identifying potential drugs against this deadly pandemic-causing disease. The scientific community has tried several existing FDA-approved drugs including different antivirals, antibiotics, steroids, to name a few, against the SARS-CoV-2 infection <sup>
<xref ref-type="bibr" rid="R9">9</xref>
</sup>. Drugs like remdesivir, tocilizumab, and flavipiravir are being given to the infected patients <sup>
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R13">13</xref>
</sup>. In addition, various druggable compounds, including natural compounds, have been reported to be effective against the virus <sup>
<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>
</sup>.</p>
<p id="P4">One such drug Mitoxantrone dihydrochloride (MTX), has been repurposed and is demonstrated to inhibit the SARS-CoV and SARS-CoV-2 virus entry into cells <sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>. Previously, the antiviral activity of MTX has been established against many other viruses such as Herpes Simplex Virus 1 (HSV-1), and Vaccinia virus <sup>
<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref>
</sup>. Additionally, the anticancer activity of this drug against lymphoma, breast cancer, and prostate cancer is very well-known <sup>
<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R22">22</xref>
</sup>. Overall, these properties make it a potential candidate to be tested for its specific binding target with SARS-CoV-2 proteins.</p>
<p id="P5">In this report, we have demonstrated the binding of anticancer compound MTX with the C-terminal region of NSP1 (NSP1-CTR) using spectroscopy-based techniques and extensively long computational simulations. According to the finding, MTX binds with NSP1-CTR in its disordered conformation and can be developed into a drug against the virus. Furthermore, this study may provide a useful insight on interacting residues of the C-terminal region for developing antiviral against SARS-CoV-2 NSP1 protein which could prevent its activity inside the host.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<p id="P6">Given the functional importance of NSP1 protein and its disordered C-terminal region, the druggability of NSP1 must be explored to identify novel inhibitors or repurposed drugs against the SARS-CoV-2. Furthermore, the blocking of NSP1-CTR may possibly restrict the binding of NSP1 with ribosomes inside host cells. Following this, we have investigated the binding of an antineoplastic drug MTX with the C-terminal tail of NSP1. Herein, we have performed binding kinetics of MTX with NSP1-CTR using fluorescence and CD spectroscopic techniques. Further, the fluorescence lifetime and anisotropy decay have been measured in the presence and absence of the drug. We have also confirmed the binding through computational modeling and docking studies.</p>
<sec id="S3">
<title>Fluorescence-based measurements</title>
<sec id="S4">
<title>Fluorescence intensity analysis</title>
<p id="P7">The binding of MTX with NSP1-CTR is studied experimentally by monitoring the changes in intrinsic fluorescence of NSP1 tryptophan (Trp<sup>161</sup>) residue. As shown in <xref ref-type="fig" rid="F1">figure 1A</xref>, the fluorescence intensity of tryptophan residue of the peptide is observed to decrease gradually on increasing the concentration of MTX in the solution. The addition of MTX has substantially quenched the tryptophan fluorescence intensity which indicates the possible binding of MTX with NSP1-CTR. As discussed in previous report on structural dynamics of NSP1-CTR, the <sub>max</sub> of the tryptophan residue occurs at 346 nm. Therefore, the dissociation constant (K<sub>d</sub>) is obtained by considering the maximum fluorescence intensity at 346 nm using the non-linear fitting of one site-specific binding. The K<sub>d</sub> for MTX-NSP1-CTR interaction is calculated to be 31.83 µM (R<sup>2</sup> = 0.9) (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p>
</sec>
<sec id="S5">
<title>Fluorescence Lifetime measurements</title>
<p id="P8">Generally, the fluorescence decay of tryptophan moiety is susceptible to changes in its surroundings. With conformational changes in proteins due to variation in temperature, viscosity, and surrounding solvent, the fluorescence lifetime changes <sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup>. Therefore, the binding and conformational changes in the NSP1-CTR-MTX complex are observed through fluorescence lifetime measurement, where the decay in fluorescence of tryptophan fluorophore was recorded. As observed in graphs depicted in <xref ref-type="fig" rid="F2">figures 2A and 2B</xref>, the average fluorescence lifetime of Trp<sup>161</sup> of NSP1-CTR shows a decreasing trend compared to the fluorescence lifetime in unbound conformation. The average lifetime of unbound protein is measured to be 1.98 ns with a chi-square (χ<sup>2</sup>) value of 1.11, whereas, in presence of 200 µM MTX, the average lifetime decreased to 1.66 ns (χ<sup>2</sup> = 1.08) (see <xref ref-type="table" rid="T1">table 1</xref>). The declining fluorescence lifetime is evident in the binding of MTX with NSP1-CTR peptide.</p>
</sec>
<sec id="S6">
<title>Time-resolved Anisotropy decay analysis</title>
<p id="P9">As aforementioned, tryptophan fluorescence is susceptible to changes in its local environment. Its global and local rotations are affected by the changes in the surroundings. Therefore, to further observe the binding of MTX with NSP1-CTR, we have performed an anisotropy decay analysis of Trp<sup>161</sup> residue. Here, the fluorescence decays of tryptophan residues in perpendicular and parallel emission polarization of light are recorded. The decay curve is fitted using a bi-exponential decay function which defines the fast (<bold>θ</bold>
<sub>1</sub>) and slow (<bold>θ</bold>
<sub>2</sub>) rotational correlational time where <bold>θ</bold>
<sub>1</sub> is the local rotation of Trp<sup>161</sup> while the <bold>θ</bold>
<sub>2</sub> is the global rotation of the peptide <sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup>. In unbound state, NSP1-CTR (30 µM) has an average rotational correlation time (τ<sub>r</sub>) equals to 4.46 ns (χ<sup>2</sup> = 1.19) (<xref ref-type="fig" rid="F3">Figure 3A &amp; 3B</xref>). Interestingly, after binding with MTX (25 µM), its average rotational correlation time decreases to 962.1 ns (χ<sup>2</sup> = 1.14) (<xref ref-type="fig" rid="F3">Figure 3C &amp; 3D</xref>). (<bold>θ</bold>
<sub>1</sub>) and (<bold>θ</bold>
<sub>2</sub>) for NSP1-CTR have been calculated to be 1.13 ns and 15.6 ns respectively, while in presence of MTX, the (<bold>θ</bold>
<sub>1</sub>) and (<bold>θ</bold>
<sub>1</sub>) are observed to be 1070.1 ns and 1.13 ns. These results correspond to the interaction of the drug with the peptide as binding of MTX has slowed the rotation of the tryptophan residue and the peptide.</p>
</sec>
</sec>
<sec id="S7">
<title>Circular dichroism-based structural alterations in NSP1-CTR</title>
<p id="P10">In order to gain insights into changes in the secondary structure of NSP1-CTR by virtue of MTX interaction, we employed CD spectroscopy and investigated the effect of the binding of MTX on its structure. The far-UV CD spectra of NSP1-CTR were recorded is presence and absence of MTX. As reported before, NSP1-CTR remains in a disordered state in isolation <sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>. Therefore, in the unbound state, the negative ellipticity at ~200 nm wavelength represents a typical spectrum corresponding to the disordered state of NSP1-CTR. However, the presence of MTX has only caused minimal fluctuations in the negative ellipticity at ~200 nm (<xref ref-type="fig" rid="F4">Figure 4</xref>). However, these CD results demonstrate that in presence of the drug MTX does not cause any noticeable structural changes in the secondary structure of the peptide, but MTX may bind with NSP1-CTR in the latter's disordered form.</p>
</sec>
<sec id="S8">
<title>Molecular docking analysis</title>
<p id="P11">As previously reported by our group, the NSP1-CTR is mainly in disordered conformation and contains helical structure forming tendencies in different environmental conditions <sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>. However, it gains alpha helix upon interacting with its binding partner i.e., 40S ribosomes (PDB ID: 6ZOJ). MD simulations of its modeled structure have also revealed the α-helical structure, therefore, we have selected the structure at last frame (at 500 ns; described as NSP1-F1 in our previous study) of NSP1-CTR from the simulation trajectory in aqueous conditions <sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>.</p>
<p id="P12">The MTX drug is docked against NSP1-CTR by enclosing the whole structure as a receptor grid, as the structure constitutes no proper binding pocket. <italic>Glide</italic> scoring function of the Schrodinger suite is employed for docking and Prime module for MM/GBSA calculation. The MTX has scored a docking score of -5.335 kcal/mol and binding energy of -47.49 kcal/mol. Besides, the strong binding with six hydrogen bonds and two salt bridge interactions has been observed between NSP1-CTR and MTX (<xref ref-type="fig" rid="F5">Figure 5</xref>). According to binding pose and ligand interaction diagram, the residues involved are Ser12 (or Ser142; according to full-length structure), Asp14 (or Asp144), Arg41 (or Arg171), and Glu25 (or Glu155).</p>
</sec>
<sec id="S9">
<title>MD Simulations analysis</title>
<p id="P13">Aiming to validate the experimental results showing the binding of MTX with NSP1-CTR peptide, we further conducted the simulation of the docked complex using two different forcefields and examined the interaction stability through computational means.</p>
<p id="P14">Firstly, the MD simulations are performed upto 1 µs with OPLS 2005 forcefield, which is implanted in Desmond package and Schrodinger's Maestro interface. According to our microsecond timescale data, the majorly disordered peptide of NSP1-CTR has shown significantly good interactions during the entire simulation period except for few frames. Based on the RMSD, the MTX bound NSP1-CTR has shown an average RMSD of ~7Å in 1 µs trajectory wherein initial 300 ns time, some fluctuations in RMSD are observed which were then stabilized till end of simulation time (<xref ref-type="fig" rid="F6">Figure 6A</xref>; <bold>upper panel</bold>). Consequently, the compactness parameter (Rg) of NSP1-CTR has also shown high variation in the simulation period, possibly due to its disordered nature (<xref ref-type="fig" rid="F6">Figure 6A</xref>; <bold>middle panel</bold>). Also, the number of hydrogen bonds has been affected due to some fluctuations and averaged out to approx. 2 for 1 µs long simulation trajectory (<xref ref-type="fig" rid="F6">Figure 6A</xref>; <bold>lower panel</bold>). As shown in <xref ref-type="fig" rid="F6">figure 6B</xref>, the fluctuations in residues hav been observed till 5Å for middle regions while higher for terminal regions. The reason could be its intrinsic property to bind with compound MTX in its disordered state which is above shown through CD spectroscopic analysis.</p>
<p id="P15">Further, this is also evident from the timeline representation of secondary structure analysis of 1 µs simulation trajectory where the majority of secondary structure element is disordered in nature (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure 1</xref>). In last, the contacts made by MTX with residues of NSP1-CTR have been observed in a significant proportion. A few residues like Tyr24 (or Tyr154) and Asp14 (or Asp144) interact with multiple bonds for most of the simulation time (<xref ref-type="fig" rid="F6">Figure 6C &amp; 6D</xref>). The structural dynamics and interaction of MTX with NSP1-CTR are shown in <xref ref-type="supplementary-material" rid="SD2">supplementary movie 1</xref>.</p>
<p id="P16">Another forcefield for examining the protein-ligand complex stability is chosen a GROMOS54A7 in Gromacs simulation package. The outcomes are in good correlation with the above simulation of longer time period. As shown in <xref ref-type="fig" rid="F7">figure 7A</xref> <bold>(upper panel)</bold>, the RMSD of the complex remains stable throughout the simulation period, with only a few noticeable fluctuations in RMSD values that are observed after 50 ns to 250 ns. The simulation trajectory has attained stability after 250 ns with an average RMSD value of 0.75 nm. In view of compactness, the MTX bound NSP1-CTR has attained an average Rg value of 1.05 nm (<xref ref-type="fig" rid="F7">Figure 7A</xref>; <bold>middle panel</bold>). Accordingly, the fluctuation in residues was also observed in terms of RMSF that is found to be varying between 0.4-0.6 nm during most of the regions. However, terminal regions have shown high flexibility as they do not constitute any structure (<xref ref-type="fig" rid="F7">Figure 7A</xref>; <bold>lower panel</bold>). The average number of hydrogen bonds are calculated to be approximately 2 for the simulation trajectory (<xref ref-type="fig" rid="F7">Figure 7B</xref>). Also, the PCA calculation is done for MTX bound NSP1-CTR, where it has shown a little scattered cluster with the distance of -2 to 2 nm (<xref ref-type="fig" rid="F7">Figure 7C &amp; 7D</xref>). The change in secondary structure is also observed concerning time where no significant change is observed, and the peptide remains majorly disordered (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure 2</xref>). Overall, both simulation results are in agreement with the experimental binding of MTX with NSP1-CTR within a favorable range.</p>
</sec>
</sec>
<sec id="S10" sec-type="discussion | conclusions">
<title>Discussion and Conclusion</title>
<p id="P17">Since the COVID-19 pandemic began, a plethora of studies on the repurposing of existing drugs and the identification of new drugs have been reported. However, none of the drugs were successful after clinical trials with high efficiency and fewer side effects. Several antivirals like Remdesivir, Flavipiravir, Lopinavir, etc., antimalarial drug Hydroxychloroquine have been tested in clinical trials as well as these have been used earlier with emergency usage authorization. These drugs have been studied against multiple target proteins of SARS-CoV and SARS-CoV-2. Among various important druggable targets of SARS-CoV-2, NSP1 protein is largely responsible for host immune response suppression. Therefore, we have studied the structure-based drug discovery against its multifunctional domain, C-terminal region, through spectroscopic and computational approaches. Here, we have investigated the binding kinetics of an anticancer compound, MTX, against NSP1-CTR.</p>
<p id="P18">Initially, MTX was developed as an analog of doxorubicin, an anthracycline, and is currently being used as an anticancer drug since the 1980s due to its better antitumor activity and less cardiotoxic properties <sup>
<xref ref-type="bibr" rid="R20">20</xref>
</sup>. The antiviral activity of this drug has also been established in several viruses. Recently, Zhang et al. has observed the role of heparan sulfate, which is present on the cell surface, as a binding mediator of ACE-2 assisted attachment of SARS-CoV and SARS-CoV-2 in host cells. Further, they have abolished that interaction using the drug MTX <sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>. It targets the heparan sulfate on host cells which ultimately prevents the viral entry <sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>. In Vaccinia Virus, it prevents viral maturation and assembly by blocking the processing of mature structural proteins <sup>
<xref ref-type="bibr" rid="R18">18</xref>
</sup>. Another study on Herpes simplex virus 1 (HSV-1) reported the binding of MTX has suppressed the viral gene expression <sup>
<xref ref-type="bibr" rid="R17">17</xref>
</sup>. Moreover, a report based on computational docking has shown that MTX has a higher docking score against SARS-CoV-2 main protease among various other drugs <sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup>.</p>
<p id="P19">NSP1-CTR is a crucial factor that suppresses the host immune system with its disorder to order transition properties inside the ribosome subunit, which ultimately restricts the mRNA from performing the translation. In this manuscript, we have performed experimentations on NSP1-CTR with literature identified an anticancer drug, Mitoxantrone. The synthetic peptide of NSP1-CTR has a single Trp at 161<sup>st</sup> position, monitored for fluorescence quenching and lifetime measurements in presence of the chosen compound MTX. The compound MTX has exerted a docking score of more than -5.0 kcal/mol and significantly good binding energy (MM-GBSA score). Its interaction with key residues like Ser142, Asp144, Lys164, Arg171 is also observed. Taking these results together, it is evident that MTX binds NSP1-CTR with excellent efficiency. To further check the structural changes in NSP1-CTR upon binding with MTX, we performed CD spectroscopy at different concentrations of MTX. The observation suggests that MTX does not change any conformation of NSP1-CTR. Based on simulations with two different forcefields, it is also clearly evident that the NSP1-CTR interacts with compound MTX in its disordered state as no structure gain property is observed in virtual simulations similar to experimental observation through CD spectroscopy. Due to the unavailability of full-length NSP1 or the N-terminal region, the binding experiments couldn’t be performed, which may or may not have any implications based on the current study.</p>
<p id="P20">Besides, we have also performed docking calculations on 665 compounds from the PubChem database, similar to Mitoxantrone or having anthracene as their parent molecule. As per our observations, a total of 33 compounds have been identified with docking scores more than Mitoxantrone (-5.3 kcal/mol). The compound with Pubchem ID: 88654295 ((2R)-2-Amino-N-[2-[[4-[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]ethyl]-3-sulfanylpropanamide), has highest docking score of -6.9 kcal/mol amongst all other compounds and have multiple interactions with Ser12 (or Ser142), Asp14 (Asp144), Asp17 (Asp147), Glu18 (Glu148), Glu25 (Glu155), Gln28 (Gln158), Thr40 (Thr170), and Arg41 (Thr171) (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure 3</xref>). The resultant compounds with docking scores and their structures are shown in the supplementary file (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure 4A</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">4B</xref> and <xref ref-type="supplementary-material" rid="SD1">supplementary table 1</xref>). Furthermore, we have also checked the interaction of around 160 similar conformers of Mitoxantrone from the PubChem database. All these conformers are anthracene molecules with the same backbone and different functional groups. In molecular docking of these compounds, most have shown similar interactions and docking score of maximum -6.1 kcal/mol. In <xref ref-type="supplementary-material" rid="SD1">supplementary table 2</xref>, we have listed the top 15 identified compounds with docking score &gt;-5.3 kcal/mol and their 2D structures shown in <xref ref-type="supplementary-material" rid="SD1">supplementary figure 5</xref>.</p>
<p id="P21">Based on these observations, it is highly plausible that the compounds like MTX and others with anthracene moiety could be explored further for experimental investigation against different targets of SARS-CoV-2. Additionally, the interactions of MTX and other similar compounds with key residues of NSP1-CTR also confer that it may inhibit the functions of NSP1 and restrict its association with the ribosomal subunit. Therefore, in the future, based on this study, it is highly possible to target NSP1 and, specifically, its CTR for developing therapeutic strategies, and further experimentation can be done using MTX as a lead or parent molecule.</p>
</sec>
<sec id="S11" sec-type="materials | methods">
<title>Material and Methods</title>
<sec id="S12" sec-type="materials">
<title>Materials</title>
<sec id="S13">
<title>NSP1 peptide</title>
<p id="P22">The sequence of NSP1-CTR (residues 131-180) “NH2-AGGHSYGADLKSFDLGDELGTDPYEDFQENWNTKHSSGVTRELMRELNGG-COOH” was retrieved from the UniProt (ID: P0DTC1.1). The peptide of purity &gt;81 % was ordered from GenScript USA.</p>
</sec>
<sec id="S14">
<title>Compound</title>
<p id="P23">Mitoxantrone (1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino) ethylamino] anthracene-9,10-dione; dihydrochloride) was purchased from Sigma-Aldrich, USA.</p>
</sec>
</sec>
<sec id="S15">
<title>Fluorescence measurement</title>
<p id="P24">Intrinsic tryptophan fluorescence of NSP1-CTR (Trp<sup>161</sup>) was monitored using a spectrofluorometer (Horiba Scientific Fluorolog, model no. 1073) with an excitation wavelength of 284 nm from 300 nm to 450 nm wavelength range at 25°C. The slits bandwidths for both excitation and emission were kept at 4 nm. Binding of MTX with NSP1-CTR was performed by titration experiment where protein concentration was kept constant at 8 μM in presence of 50 mM sodium phosphate (pH 7.4) buffer. The inner filter effect in fluorescence data was corrected using the following equation <sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup>: <disp-formula id="FD1">
<mml:math id="M1">
<mml:mrow>
<mml:msub>
<mml:mtext>F</mml:mtext>
<mml:mrow>
<mml:mtext>cor</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>F</mml:mtext>
<mml:mrow>
<mml:mtext>obs</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>∗</mml:mo>
<mml:mtext>antilog</mml:mtext>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mrow>
<mml:mtext>ex</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mrow>
<mml:mtext>em</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p id="P25">where F<sub>obs</sub> and F<sub>cor</sub> are measured and corrected fluorescence intensities, respectively. A<sub>ex</sub> and A<sub>em</sub> represents the absorbance of the sample at excitation and emission wavelengths, respectively.</p>
</sec>
<sec id="S16">
<title>Fluorescence lifetime measurement</title>
<p id="P26">The fluorescence lifetime of tryptophan residue (Trp<sup>161</sup>) in NSP1-CTR in absence and presence of MTX was measured using the Horiba Scientific DeltaFlex TCSPC system at 25°C. The samples were excited at 284 nm using the nanoLED as a light source. The wavelength of the emission monochromator was set at 346 nm. The measurement range was adjusted to 400 ns with bandpass of 32 nm and peak preset of 10000 counts. Ludox was used to correct the instrument response factor (IRF) at 284 nm. The concentration of NSP1-CTR was kept constant at 8 μM and in presence of 50 mM sodium phosphate (pH 7.4) buffer. Finally, the three exponential decay function fitting was used to obtain the tryptophan lifetimes.</p>
</sec>
<sec id="S17">
<title>Circular dichroism (CD) measurement</title>
<p id="P27">Far-UV CD spectra of NSP1-CTR in 50 mM sodium phosphate (pH 7.4) buffer were recorded using Jasco-1500 spectrophotometer from 190 nm – 240 nm, using 1 mm quartz cuvette (Hellma, Plainview, NY, USA) at 25°C. The bandwidth was kept at 4 nm for all measurements. For CD spectra of NSP1 C-terminal peptide, a control spectrum consisting of only buffer was subtracted from the peptide spectrum. To analyze the CD spectra of peptide in presence of compounds, CD spectra of compounds were subtracted from the peptide spectrum. For all measurements, the protein concentration was kept at 25 μM. All the measurements were smoothened by 5 points through the adjacent-averaging method in Origin software.</p>
</sec>
<sec id="S18">
<title>Time-resolved Anisotropy decay measurement</title>
<p id="P28">To confirm the binding of NSP1-CTR and MTX, time-resolved anisotropy decay was measured using DeltaFlex TCSPC system (Horiba Scientific) at 25ºC. A 1 ml pathlength quartz cuvette was used to record the measurements where the measurement range was set up to 200 ns. The bandpass of 16 nm, peak preset of 1,000 counts, and repetition rate of 1 MHz were used during experimentation. The protein concentration was kept constant at 30 μM. At 284 nm wavelength, ludox was used for adjusting the instrument response factor (IRF). Using the data analysis software DAS6 (Horiba Scientific), the resultant anisotropy decay curves were fitted into a bi-exponential decay function <sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup>: <disp-formula id="FD2">
<mml:math id="M2">
<mml:mrow>
<mml:mi>r</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>r</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>A</mml:mi>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mi>exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>θ</mml:mi>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mi>exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>θ</mml:mi>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p id="P29">where, anisotropy at time <italic>t</italic> is denoted by <italic>r</italic>(<italic>t</italic>) and initial anisotropy is denoted by <italic>r</italic>
<sub>0</sub>, and <italic>A</italic>
<sub>1</sub> and <italic>A</italic>
<sub>2</sub> defines the rotational correlation time □<sub>1</sub> and □<sub>2</sub>, respectively.</p>
</sec>
<sec id="S19">
<title>Molecular Docking</title>
<p id="P30">The docking of MTX against the simulated structure of NSP1-CTR was performed and the molecular interactions between the complex were analyzed using the Glide XP (Extra Precision) program in the Schrodinger suite <sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup>. The parameters for protein structure and ligand preparation are kept as previously reported <sup>
<xref ref-type="bibr" rid="R27">27</xref>
</sup>. Grid coordinates were set as 28.0, 24.0, and 33.18 Å for X, Y, and Z, respectively. The binding energy of complex was calculated using Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) approach embedded in Prime module of Schrodinger <sup>
<xref ref-type="bibr" rid="R28">28</xref>
</sup>.</p>
</sec>
<sec id="S20">
<title>Molecular Dynamics Simulations</title>
<p id="P31">The MD simulations were performed to observe the binding of MTX with NSP1-CTR using two different forcefields viz. OPLS 2005 forcefield in Desmond simulation package (v2018.4) <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> and GROMOS54A7 forcefield, utilizing the in-house cluster facility, simulation of the complex was achieved in Gromacs v5.1.2 <sup>
<xref ref-type="bibr" rid="R30">30</xref>
</sup>.</p>
<p id="P32">We have used our previously reported protocol for simulations of protein-ligand complex using Desmond <sup>
<xref ref-type="bibr" rid="R31">31</xref>
</sup>. Briefly, we have utilized TIP3P water model along with counterions present in the system for charge neutralization. Nose-Hoover and Martina-Thomas-Klein methods were used for temperature and pressure controlling in equilibration and final production runs. A total of one microsecond (µs) simulation was performed. For MD simulations in Gromacs, the SPC water model was added and charge neutralization was done by adding counterions in the simulation setup. The energy minimization was performed by implementing the 50,000 steps of steepest-descent algorithm with Verlet cut-off scheme to calculate the neighboring interactions. Further, equilibration process was carried out under NPT and NVT conditions for 1ns. Parrinello-Rahman and V-rescale methods were utilized for pressure and temperature coupling, respectively. The Gromacs topology of the compound was generated using PRODRG server <sup>
<xref ref-type="bibr" rid="R32">32</xref>
</sup>. LINCS algorithm was used for calculating bond parameters <sup>
<xref ref-type="bibr" rid="R33">33</xref>
</sup>. Furthermore, the simulation analysis parameters are analyzed using gmx toolbox, including rms, rmsf, gyrate, hbond, covar, and anaeig commands. For visualization, UCSF Chimera <sup>
<xref ref-type="bibr" rid="R34">34</xref>
</sup> and Schrodinger Maestro were used.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>supplementary information</label>
<media xlink:href="EMS135056-supplement-supplementary_information.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="N66561" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>supplementary movie 1</label>
<media xlink:href="EMS135056-supplement-supplementary_movie_1.mpg" mimetype="video" mime-subtype="mpeg" id="N66570" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S21">
<title>Acknowledgments</title>
<p>All the authors would like to thank IIT Mandi and HPC utility for providing facilities. RG would like to acknowledge the Department of Biotechnology, Govt of India (BT/11/IYBA/2018/06) and SERB-India (CRG/2019/005603). TB is grateful to the Department of Science and Technology, Govt. of India, for her INSPIRE fellowship for Funding.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P33">
<bold>Authors’ contribution:</bold> RG: Conception, design, and review of the manuscript. PK, and TB: acquisition and interpretation of data, writing of the manuscript. PK and TB have contributed equally.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P34">
<bold>Conflict of Interest:</bold> All authors declare that they have no conflict of interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snijder</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>van der Meer</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zevenhoven-Dobbe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Onderwater</surname>
<given-names>JJM</given-names>
</name>
<name>
<surname>van der Meulen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koerten</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Mommaas</surname>
<given-names>AM</given-names>
</name>
</person-group>
<source>J Virol</source>
<year>2006</year>
<volume>80</volume>
<fpage>5927</fpage>
<lpage>5940</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<source>Front Microbiol</source>
<year>2020</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thoms</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buschauer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ameismeier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koepke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Denk</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirschenberger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kratzat</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mackens-Kiani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stürzel</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group>
<source>Science (80-)</source>
<year>2020</year>
<volume>369</volume>
<fpage>1249</fpage>
<lpage>1255</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karousis</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Jomaa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scaiola</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Echeverria</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gurzeler</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Leibundgut</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mühlemann</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>N</given-names>
</name>
</person-group>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>959</fpage>
<lpage>966</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>Curr Res Virol Sci</source>
<year>2021</year>
<volume>2</volume>
<elocation-id>100007</elocation-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miorin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Makio</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dehghan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Esparza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kehrer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hobman</surname>
<given-names>TC</given-names>
</name>
<etal/>
</person-group>
<source>Sci Adv</source>
<year>2021</year>
<volume>7</volume>
<elocation-id>eabe7386</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lapointe</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Grosely</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Puglisi</surname>
<given-names>JD</given-names>
</name>
</person-group>
<source>Proc Natl Acad Sci U S A</source>
<pub-id pub-id-type="doi">10.1073/pnas.2017715118</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y</given-names>
</name>
</person-group>
<source>Med Res Rev</source>
<year>2021</year>
<volume>41</volume>
<fpage>5</fpage>
<lpage>28</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
</person-group>
<source>Proc Natl Acad Sci U S A</source>
<pub-id pub-id-type="doi">10.1073/pnas.2024302118</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
</person-group>
<source>J Med Virol</source>
<year>2020</year>
<volume>92</volume>
<fpage>814</fpage>
<lpage>818</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<source>Engineering</source>
<year>2020</year>
<volume>6</volume>
<fpage>1192</fpage>
<lpage>1198</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
</person-group>
<source>medRxiv</source>
<pub-id pub-id-type="doi">10.1101/2020.03.22.20040758</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ohmagari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Asperges</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Castagna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Feldt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lescure</surname>
<given-names>F-X</given-names>
</name>
<name>
<surname>Nicastri</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>2327</fpage>
<lpage>2336</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayatollahi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tsouh Fokou</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Mahady</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Ansar Rasul Suleria</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Krishna Kapuganti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gadhave</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<source>Front Pharmacol</source>
<year>2021</year>
<volume>12</volume>
<fpage>575877</fpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Twilley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Esmear</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oosthuizen</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lall</surname>
<given-names>N</given-names>
</name>
</person-group>
<source>Front Pharmacol</source>
<year>2020</year>
<volume>11</volume>
<fpage>1514</fpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CZ</given-names>
</name>
<name>
<surname>Swaroop</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>AQ</given-names>
</name>
<name>
<surname>Pradhan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<source>Cell Discov</source>
<year>2020</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhuo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F</given-names>
</name>
</person-group>
<source>BMC Microbiol</source>
<year>2019</year>
<volume>19</volume>
<fpage>1</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ciro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smee</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Djaballah</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shuman</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>J Virol</source>
<year>2007</year>
<volume>81</volume>
<fpage>13392</fpage>
<lpage>13402</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bell</surname>
<given-names>DH</given-names>
</name>
</person-group>
<source>BBA - Gene Struct Expr</source>
<year>1988</year>
<volume>949</volume>
<fpage>132</fpage>
<lpage>137</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<source>Neurology</source>
<publisher-name>Neurology</publisher-name>
<year>2004</year>
<volume>63</volume>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Figgitt</surname>
<given-names>DP</given-names>
</name>
</person-group>
<source>CNS Drugs</source>
<year>2004</year>
<volume>18</volume>
<fpage>379</fpage>
<lpage>396</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enache</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toader</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Enache</surname>
<given-names>MI</given-names>
</name>
</person-group>
<source>Molecules</source>
<year>2016</year>
<volume>21</volume>
<fpage>1</fpage>
<lpage>17</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Lakowicz</surname>
<given-names>JR</given-names>
</name>
</person-group>
<source>Principles of fluorescence spectroscopy</source>
<publisher-loc>Spain</publisher-loc>
<publisher-name>Springer</publisher-name>
<year>2006</year>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Royer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Scarlata</surname>
<given-names>SF</given-names>
</name>
</person-group>
<source>Fluorescence Approaches to Quantifying Biomolecular Interactions</source>
<publisher-name>Elsevier Inc</publisher-name>
<edition>1st edn</edition>
<year>2008</year>
<volume>450</volume>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lokhande</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Doiphode</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vyas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swamy</surname>
<given-names>KV</given-names>
</name>
</person-group>
<source>J Biomol Struct Dyn</source>
<pub-id pub-id-type="doi">10.1080/07391102.2020.1805019</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friesner</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Repasky</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Greenwood</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Halgren</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Sanschagrin</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Mainz</surname>
<given-names>DT</given-names>
</name>
</person-group>
<source>J Med Chem</source>
<year>2006</year>
<volume>49</volume>
<fpage>6177</fpage>
<lpage>6196</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bhardwaj</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gehi</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Kapuganti</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>J Biomol Struct Dyn</source>
<year>2020</year>
<fpage>1</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Pincus</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>TJF</given-names>
</name>
<name>
<surname>Honig</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Friesner</surname>
<given-names>RA</given-names>
</name>
</person-group>
<source>Proteins Struct Funct Bioinforma</source>
<year>2004</year>
<volume>55</volume>
<fpage>351</fpage>
<lpage>367</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Bowers</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dror</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Gregersen</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Klepeis</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kolossvary</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moraes</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sacerdoti</surname>
<given-names>FD</given-names>
</name>
<etal/>
</person-group>
<conf-name>ACM/IEEE SC 2006 Conf</conf-name>
<year>2006</year>
<fpage>43</fpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendsen</surname>
<given-names>HJC</given-names>
</name>
<name>
<surname>van der Spoel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Drunen</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>Comput Phys Commun</source>
<year>1995</year>
<volume>91</volume>
<fpage>43</fpage>
<lpage>56</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bhardwaj</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
</person-group>
<year>2021</year>
<volume>13</volume>
<fpage>1341</fpage>
<lpage>1352</lpage>
<pub-id pub-id-type="doi">10.4155/fmc-2021-0087</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Aalten</surname>
<given-names>DMF</given-names>
</name>
</person-group>
<source>J Comput Aided Mol Des</source>
<year>1996</year>
<volume>10</volume>
<fpage>255</fpage>
<lpage>262</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bekker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Berendsen</surname>
<given-names>HJC</given-names>
</name>
<name>
<surname>Fraaije</surname>
<given-names>JGEM</given-names>
</name>
</person-group>
<source>J Comput Chem</source>
<year>1997</year>
<volume>18</volume>
<fpage>1463</fpage>
<lpage>1472</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Ferrin</surname>
<given-names>TE</given-names>
</name>
</person-group>
<source>J Comput Chem</source>
<year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Tryptophan (Trp<sup>161</sup>) fluorescence emission analysis of NSP1-CTR peptide with MTX. <bold>(A)</bold> The decreasing intrinsic fluorescence intensity of NSP1-CTR upon addition of MTX in increasing concentrations (0 to 300 µM). <bold>(B)</bold> The fluorescence intensity at 346 nm is plotted against the concentration of MTX. <bold>Inset:</bold> shows the non-linear fitting of one-site specific binding with the calculated dissociation constant.</p>
</caption>
<graphic xlink:href="EMS135056-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Assessment of Trp<sup>161</sup> by using fluorescence lifetime measurement. <bold>(A)</bold> Fluorescence lifetime decay curve of NSP1-CTR peptide in absence and presence of drug MTX at four increasing concentrations. <bold>(B)</bold> Illustration of decrease in average fluorescence lifetime of Trp<sup>161</sup> with increasing concentration of MTX.</p>
</caption>
<graphic xlink:href="EMS135056-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Fluorescence anisotropy decay measurements of NSP1-CTR.</title>
<p>(<bold>A</bold>) the conformational dynamics in unbound state of NSP1-CTR (30 µM), and (<bold>B</bold>) in the bound state with compound MTX (25 µM). Figure (<bold>C</bold>) and (<bold>D</bold>) depict the residual of the fitting curve corresponding to unbound and bound state of NSP1-CTR.</p>
</caption>
<graphic xlink:href="EMS135056-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Circular Dichroism spectra of NSP1 C-terminal upon interaction with compound MTX on varying concentrations from 0 to 200 µM in comparison with the unbound state of NSP1-CTR at 25 µM.</p>
</caption>
<graphic xlink:href="EMS135056-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>In-silico interaction analysis</title>
<p>Molecular docking of Mitoxantrone against NSP1-CTR by enclosing whole structure in the grid. <bold>(A)</bold> The surface representation of NSP1-CTR with docked drug MTX, <bold>(B)</bold> 3D cartoon representation of protein-ligand binding pose, and <bold>(C)</bold> 2D interaction showing interacting residues of NSP1-CTR with MTX is depicted.</p>
</caption>
<graphic xlink:href="EMS135056-f005"/>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<title>Molecular dynamics simulation analysis of MTX bound NSP1-CTR using OPLS 2005 forcefield</title>
<p>
<bold>(A)</bold> RMSD, Rg, of C-alpha (Cα) atoms and hydrogen bonds (from up to down), (<bold>B)</bold> RMSF analysis highlighting interactions of NSP1-CTR formed with MTX, (C) Histogram plot for representation of the fraction of interaction with residues throughout the simulations where hydrogen bonds (green), water bridges (blue), hydrophobic (purple), and ionic (red) are shown, and one bar with multiple colors shows multiple interactions with that specific residue and (D) Timeline representation of interacting residues where dark color depicts more number of interactions.</p>
</caption>
<graphic xlink:href="EMS135056-f006"/>
</fig>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption>
<title>Molecular dynamics simulation analysis of MTX bound NSP1-CTR using GROMOS 54A7 forcefield</title>
<p>
<bold>(A)</bold> RMSD, Rg, and RMSF (from up to down), (<bold>B)</bold> hydrogen bonds analysis, <bold>(C)</bold> Eigenvector vs. Eigenvalue plot, and <bold>(D)</bold> principal component analysis of last 20 ns simulation trajectory.</p>
</caption>
<graphic xlink:href="EMS135056-f007"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Decreasing average fluorescence lifetime of Trp<sup>161</sup> of NSP1-CTR upon addition of MTX.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="bottom">Mitoxantrone Concentration (μM)</th>
<th align="center" valign="bottom">τ<sub>1</sub> ± <italic>s</italic> (ns)</th>
<th align="center" valign="bottom">τ<sub>2</sub> ± <italic>s</italic> (ns)</th>
<th align="center" valign="bottom">τ<sub>3</sub> ± <italic>s</italic> (ns)</th>
<th align="center" valign="bottom">τ (average lifetime, ns)</th>
<th align="center" valign="bottom">χ<sup>2</sup> - value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="bottom">
<bold>0 (Only NSP1-CTR; 7.5 μM)</bold>
</td>
<td align="center" valign="bottom">2.42 ± 0.10</td>
<td align="center" valign="bottom">0.61 ± 0.02</td>
<td align="center" valign="bottom">5.28 ± 0.04</td>
<td align="center" valign="bottom">1.98</td>
<td align="center" valign="bottom">1.11</td>
</tr>
<tr>
<td align="center" valign="bottom">
<bold>25</bold>
</td>
<td align="center" valign="bottom">2.31 ± 0.06</td>
<td align="center" valign="bottom">5.12 ± 0.06</td>
<td align="center" valign="bottom">0.63 ± 0.02</td>
<td align="center" valign="bottom">1.81</td>
<td align="center" valign="bottom">1.06</td>
</tr>
<tr>
<td align="center" valign="bottom">
<bold>50</bold>
</td>
<td align="center" valign="bottom">2.23 ± 0.08</td>
<td align="center" valign="bottom">5.02 ± 0.05</td>
<td align="center" valign="bottom">0.59 ± 0.02</td>
<td align="center" valign="bottom">1.77</td>
<td align="center" valign="bottom">1.13</td>
</tr>
<tr>
<td align="center" valign="bottom">
<bold>100</bold>
</td>
<td align="center" valign="bottom">2.26 ± 0.08</td>
<td align="center" valign="bottom">4.96 ± 0.06</td>
<td align="center" valign="bottom">0.62 ± 0.02</td>
<td align="center" valign="bottom">1.76</td>
<td align="center" valign="bottom">1.24</td>
</tr>
<tr>
<td align="center" valign="bottom">
<bold>200</bold>
</td>
<td align="center" valign="bottom">2.24 ± 0.08</td>
<td align="center" valign="bottom">4.91 ± 0.06</td>
<td align="center" valign="bottom">0.58 ± 0.01</td>
<td align="center" valign="bottom">1.66</td>
<td align="center" valign="bottom">1.08</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p id="P35">The quoted errors are sample standard deviations as ± <italic>s</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
